Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

TidsskriftEuropean Annals of Allergy and Clinical Immunology
Udgave nummer6
Sider (fra-til)284-285
Antal sider2
StatusUdgivet - nov. 2017

ID: 189622756